Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US National Institute of Allergy and Infectious Diseases (NIAID) has chosen Destiny Pharma's lead drug XF-73 to evaluate in Phase 1 clinical trial, under a clinical trial agreement signed between the two parties.
Subscribe to our email newsletter
XF-73, a novel dicationic porphyrin, is under development for the prevention of post-surgical Staphylococcal infections.
The Phase 1 trial aims to evaluate the safety, tolerability and preliminary anti-Staphylococcal activity of the drug.
The drug has demonstrated its ability to prevent the emergence of antibacterial resistance, compared to the currently available antibiotics.
Destiny Pharma CEO Bill Love said they look forward to working with this institution and the experienced clinical research contractors it brings to initiate XF-73’s clinical evaluation in the US.